Traveler's Diarrhea - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Traveler''s Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Traveler''s Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traveler''s Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler''s Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape of Traveler''s Diarrhea
  
• The report reviews pipeline therapeutics for Traveler''s Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report reviews key players involved Traveler''s Diarrhea therapeutics and enlists all their major and minor projects
  
• The report assesses Traveler''s Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report summarizes all the dormant and discontinued pipeline projects
  
• The report reviews latest news related to pipeline therapeutics for Traveler''s Diarrhea

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand important and diverse types of therapeutics under development for Traveler''s Diarrhea
  
• Identify potential new clients or partners in the target demographic
  
• Develop strategic initiatives by understanding the focus areas of leading companies
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Traveler''s Diarrhea pipeline depth and focus of Indication therapeutics
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Traveler''s Diarrhea Overview 7
Therapeutics Development 8
Pipeline Products for Traveler''s Diarrhea - Overview 8
Pipeline Products for Traveler''s Diarrhea - Comparative Analysis 9
Traveler''s Diarrhea - Therapeutics under Development by Companies 10
Traveler''s Diarrhea - Therapeutics under Investigation by Universities/Institutes 11
Traveler''s Diarrhea - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Traveler''s Diarrhea - Products under Development by Companies 15
Traveler''s Diarrhea - Products under Investigation by Universities/Institutes 16
Traveler''s Diarrhea - Companies Involved in Therapeutics Development 17
Cosmo Pharmaceuticals NV 17
GlaxoSmithKline Plc 18
Nippon Shinyaku Co., Ltd. 19
Prokarium Limited 20
Scandinavian Biopharma Holding AB 21
Sigmoid Pharma Limited 22
Traveler''s Diarrhea - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Etvax - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GVXNSD-133 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
IMSUTMR-1501 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
prulifloxacin - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
rifamycin CR - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Typhetec - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Vaccine for Traveler''s Diarrhea - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Vaccine for Traveler''s Diarrhea - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler''s Diarrhea - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Traveler''s Diarrhea - Dormant Projects 44
Traveler''s Diarrhea - Discontinued Products 45
Traveler''s Diarrhea - Product Development Milestones 46
Featured News & Press Releases 46
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX 46
Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea 46
Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers'' Diarrhea 47
Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 48
Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 49
Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 49
Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 50
Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 51
Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 51
Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 52
Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers’ Diarrhea 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Number of Products under Development for Traveler''s Diarrhea, H2 2016 8
Number of Products under Development for Traveler''s Diarrhea - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Traveler''s Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2016 17
Traveler''s Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016 18
Traveler''s Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 19
Traveler''s Diarrhea - Pipeline by Prokarium Limited, H2 2016 20
Traveler''s Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016 21
Traveler''s Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Traveler''s Diarrhea - Dormant Projects, H2 2016 44
Traveler''s Diarrhea - Discontinued Products, H2 2016 45

List of Figures

Number of Products under Development for Traveler''s Diarrhea, H2 2016 8
Number of Products under Development for Traveler''s Diarrhea - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Targets, H2 2016 24
Number of Products by Stage and Top 10 Targets, H2 2016 24
Number of Products by Mechanism of Actions, H2 2016 26
Number of Products by Stage and Mechanism of Actions, H2 2016 26
Number of Products by Routes of Administration, H2 2016 28
Number of Products by Stage and Routes of Administration, H2 2016 28
Number of Products by Molecule Types, H2 2016 30
Number of Products by Stage and Molecule Types, H2 2016 30